When Imatinib Stops Working: — Resistance and What Comes Next

Not automatically. Most resistance in CML is detected at the molecular level, meaning the PCR number rises but you may have no symptoms and your blood count may still look normal. This is the best time to act. Resistance caught early, before the disease progresses to an accelerated or blast phase, gives you more treatment options and keeps the pathway simpler. Your oncologist will describe the phase of your disease alongside the resistance finding — these are two separate pieces of information, and you are entitled to have both explained clearly.

It depends on where things stand when resistance is detected. If your PCR is rising but your blood counts are stable and there is no concern about disease progression, mutation testing may be done from a blood sample alone. A bone marrow biopsy is more likely if your blood count has changed significantly, if there is a concern the disease may have progressed to a more advanced phase, or if the blood sample does not produce a clear mutation result. Your team will tell you which test they are ordering and why.

The mutation result usually takes one to three weeks to come back, depending on the laboratory. Once the result is available, most teams aim to make the switch promptly. Imatinib is generally continued until the new drug is ready, because stopping treatment without a replacement is not advisable. Your team will give you a specific timeline and tell you what to do if you run low on imatinib in the meantime.

They are different rather than uniformly worse. Each second-generation TKI has its own side effect profile. Dasatinib is associated with fluid around the lungs in some patients. Nilotinib is associated with cardiovascular effects and is not recommended if you have certain heart or blood vessel conditions. Bosutinib tends to cause more gut symptoms initially. Your oncologist will weigh these against your own medical history when choosing between them. Most side effects are manageable when reported early rather than waited out.

Dose escalation of imatinib was used in earlier years when fewer alternatives existed. European LeukemiaNet guidance now generally favours switching to a more potent TKI over increasing the imatinib dose, because the response to a targeted switch is more reliable and the resistance mechanism is directly addressed. There may be individual situations where a dose adjustment is discussed, but this is not the standard approach for confirmed resistance with a mutation identified.

Most people who develop resistance to imatinib respond to a second-line TKI, and many achieve deep molecular responses that allow them to continue living well with CML managed as a long-term condition. The pathway does not end at imatinib. For a smaller proportion who need a third drug, or who progress to a more advanced phase, treatment becomes more intensive — which is why catching resistance early matters. We do not yet have long-term data for all the newer agents, and your oncologist will be honest about what is and is not known for your specific situation.